DSG Capital Advisors’s Pfizer PFE Stock Holding History

DSG Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,200	Closed	-$202K	–	125
2026 Q1	$202K	Buy	+7,200	New	+$192K	0.03%	123
2025 Q1	–	Sell	-10,606	Closed	-$281K	–	124
2024 Q4	$281K	Buy	+10,606	New	+$288K	0.05%	108

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DSG Capital Advisors's PFE Position: Q2 2026 in Review

DSG Capital Advisors sold out of Pfizer (PFE) in Q2 2026, closing a stake of 7,200 shares — an estimated $202K sold.

DSG Capital Advisors first reported a position in PFE in Q4 2024 and held it in 2 quarters. The position peaked at $281K in Q4 2024. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

DSG Capital Advisors reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
DSG Capital Advisors sold 7,200 Pfizer shares in Q2 2026, an estimated $202K.
DSG Capital Advisors first reported a position in Pfizer in Q4 2024 and held it in 2 quarters.
DSG Capital Advisors's Pfizer position peaked at $281K in Q4 2024.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on DSG Capital Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.